Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sutro Biopharma (STRO) Research & Development (2017 - 2025)

Sutro Biopharma (STRO) has disclosed Research & Development for 9 consecutive years, with $36.6 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 48.42% to $36.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $166.4 million through Dec 2025, down 33.97% year-over-year, with the annual reading at $166.4 million for FY2025, 33.97% down from the prior year.
  • Research & Development hit $36.6 million in Q4 2025 for Sutro Biopharma, down from $39.9 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $71.0 million in Q4 2024 to a low of $22.6 million in Q1 2021.
  • Historically, Research & Development has averaged $42.0 million across 5 years, with a median of $39.6 million in 2023.
  • Biggest five-year swings in Research & Development: surged 49.12% in 2024 and later plummeted 48.42% in 2025.
  • Year by year, Research & Development stood at $29.9 million in 2021, then surged by 44.13% to $43.1 million in 2022, then rose by 24.64% to $53.8 million in 2023, then soared by 32.12% to $71.0 million in 2024, then tumbled by 48.42% to $36.6 million in 2025.
  • Business Quant data shows Research & Development for STRO at $36.6 million in Q4 2025, $39.9 million in Q3 2025, and $38.3 million in Q2 2025.